X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 15, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15

Reporting Person: SCHULMAN AMY W (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$8.06	2025-05-14	Common Stock (6482)		Direct

Footnotes

F1: This option was granted on May 15, 2015 and vests over four years, with 25% of the original 6,482 sharesunderlying the option having vested on May 15, 2016 and 2.0833% of the original 6,482 shares vesting monthly thereafter, subject to continued service.